Thalia Therapeutics (LSE:THAT) has completed the initial chemistry synthesis of the siRNA gene-silencing medicines for THAT-002, its cardiovascular programme targeting both PCSK9 and lipoprotein(a). In vitro studies with WuXi AppTec are under way, with in vivo work scheduled for later in the fourth quarter of 2026.

What was announced

On 25 September 2026, Thalia Therapeutics plc announced that its RNA gene-silencing cardiovascular programme had advanced. The company said it has "completed the initial chemistry synthesis of the siRNA gene-silencing medicines for its cardiovascular programme, THAT-002."

THAT-002 is designed to address PCSK9 and lipoprotein(a), or Lp(a), which the company describes as two factors of cardiovascular disease risk. The stated objective is to develop "a single therapeutic that addresses both targets to reduce global cardiovascular risk." The company describes the candidate as a potentially long-acting, dual-acting siRNA therapeutic aimed at atherosclerotic cardiovascular disease, tackling two independent drivers of risk at once.

Where the programme stands

The preclinical work began in September 2026 with WuXi AppTec (Hong Kong) Limited. With the initial synthesis complete, in vitro studies are now under way, ahead of in vivo work that is scheduled for later in the fourth quarter of 2026. According to the announcement, these studies will "inform further preclinical development of THAT-002 as it progresses toward IND-enabling studies."

The company said the milestone was reached on time and on budget. It has not disclosed the budget for the programme, the cost of the WuXi AppTec work or how the next stages will be funded.

Thalia's stated objective, once preclinical work is complete, is to file with the US Food and Drug Administration (FDA) for human clinical studies. No target date for that filing is given. The announcement does not specify the dosing interval being targeted, the patient populations that might eventually be studied, or what measures the in vitro and in vivo studies will assess. It contains no efficacy or safety data.

Management comment

Chief executive Dr David Solomon said: "Completing the initial chemistry synthesis allows us to move THAT-002 into cell-based tests." He described the milestone as "an early but important step" and added: "This gene-silencing programme has the promise of reducing global cardiovascular risk." That view represents the company's aspiration for the programme; THAT-002 has not yet entered in vivo testing or clinical trials.

The wider pipeline

Thalia (LSE:THAT) describes itself as a developer of "RNA-based therapeutics and delivery technologies across oncology and cardiovascular disease". Alongside THAT-002, its portfolio includes miRisten (THAT-001), which is in clinical development for acute myeloid leukaemia, and Nuvec (THAT-003), its proprietary delivery technology. The announcement does not provide an update on either of these programmes, and it does not say whether Nuvec is intended to play any role in THAT-002.

THAT-002 therefore sits at an earlier stage than miRisten within the portfolio. Its progress over the coming months rests on the preclinical steps the company has outlined, beginning with the cell-based work now in progress.

What to watch next

The near-term milestones set out by the company are the results of the in vitro studies now in progress and the start of in vivo work, scheduled for later in the fourth quarter of 2026. Beyond that, the company expects the preclinical programme to progress towards IND-enabling studies, with the longer-term objective of an FDA filing to begin human trials. Investors may look for further detail on timelines, costs and funding for these stages, none of which was quantified in this announcement.